NanoCellect Biomedical, Inc.
NanoCellect Biomedical, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at NanoCellect Biomedical, Inc..
NanoCellect Biomedical, Inc. is a company.
Key people at NanoCellect Biomedical, Inc..
Key people at NanoCellect Biomedical, Inc..
NanoCellect Biomedical, Inc. develops and manufactures microfluidic cell sorters for biomedical research, focusing on gentle, precise cell sorting with high viability for applications like genomics, antibody discovery, stem cell research, gene editing, and cell line development.[1][2][3] Its key products—the WOLF G2, VERLO Image-Guided Cell Sorter, and N1 Single-Cell Dispenser—serve academic labs, biotech/pharma companies, and research institutions by enabling benchtop sorting into 96- or 384-well plates without expert operators or cross-contamination risks.[2][4][5] Founded in 2009 (with some sources noting 2011), the company has raised $85.42M in funding up to Series E stage, with the last round of $28.93M about two years ago, reflecting strong growth momentum in the expanding single-cell analysis market driven by cellular therapies and life sciences research.[1][7]
NanoCellect Biomedical emerged from a team of scientists and engineers addressing a core challenge in biological research: effective, easy, high-quality cell sorting without the complexity of traditional systems.[2] Founded in 2009 in San Diego, California (formerly known as NanoSort), it pioneered microfluidic chip technology combined with intuitive software to democratize flow cytometry.[1][2][7] Early traction came from its WOLF Cell Sorter, designed for small labs and companies unable to access bulky alternatives, enabling breakthroughs in single-cell omics and drug discovery; this humanizes the company as a toolmaker born from researcher frustrations, evolving into advanced models like VERLO for imaging-based sorting.[2][5][7]
NanoCellect rides the single-cell analysis boom, fueled by demand for high-quality reagents, cell-based therapeutics, and advanced workflows in genomics, CRISPR screens, and personalized medicine amid rising cancer incidences and R&D investments.[1][3] Timing aligns with the consumables-dominated market (leading in 2023 forecasts), where academic labs—its fastest-growing end-user—adopt tools for reproducible results in drug discovery and diagnostics.[1] It influences the ecosystem by empowering smaller biotechs with core facility-level tech, accelerating clonal outgrowth, sequencing prep, and therapeutic development while reducing barriers in a field shifting toward microfluidics for precision and scalability.[2][3][6]
NanoCellect is poised for expansion with its Series E funding and product roadmap enhancing imaging/multiparameter sorting, targeting the surging cell therapy and omics markets.[1][5] Trends like AI-driven analysis, advanced cellular therapies, and single-cell multi-omics will shape its path, potentially driving acquisitions or IPO as biotech funding rebounds. Its influence may evolve by standardizing gentle sorting in routine workflows, bridging research-to-clinic gaps and amplifying discoveries from benchtop to bedside—reinforcing its role as an accessible enabler in biomedical innovation.[1][2][3]
